Skip to content

Circulating biomarkers in hormone-producing tumors

Exploring novel circulating biomarkers in hormone-producing endocrine tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1040200050
Enrollment
420
Registered
2020-10-08
Start date
2020-10-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hormone producing endocrine tumor hormone-producing endocrine tumor

Interventions

None listed

Sponsors

Takamura Toshinari
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Selection criteria 1) From April 1, 2002 to December 31, 2023, a hormone-producing endocrine tumor that was diagnosed by functional tests and imaging tests at our hospital, endocrinology / metabolism internal medicine, former first internal medicine, and former second internal medicine. In addition, patients with abnormal metabolism (obesity, hypertension, abnormal glucose metabolism, cardiovascular disease, non-alcoholic fatty liver disease) who are not diagnosed as hormone production, and patients with non-hormone-producing endocrine tumors. Each diagnostic criterion follows each guideline and consensus statement. 2) Being over 20 years old and able to go to the hospital. 3) The functions of major organs (below) are retained by clinical examination within 30 days before registration. 1 White blood cell : 3,000 = 10.0 g / dL 3 Platelet count: Platelet >= 50,000 / mcL 4 Total bilirubin: T.Bil <= 2.0 mg / dL 5 Serum creatinine: Cr <= 2.5 mg / dL 4) Patients who have received sufficient explanation before participating in this study, and who have obtained sufficient understanding and voluntary written consent of the patient.

Exclusion criteria

Exclusion criteria: Exclusion criteria 1) using oral or intravenous steroids. 2) serious infection, before or after surgery, or if you have serious trauma. 3) malignant tumor (including a history). 4) the principal investigator or the investigator judges that it is inappropriate as the subject of this research.

Design outcomes

Primary

MeasureTime frame
changes in the candidate circulating biomarker that is newly detected in this study after the treatment of its hormone-producing endocrine tumor

Secondary

MeasureTime frame
correlation between the levels of the candidate circulating biomarker and the parameters of the physical exam or biochemistry

Contacts

Public ContactYujiro Nakano

Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

yujironakano@staff.kanazawa-u.ac.jp+81-76-265-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026